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The first implanted fixed rate pumps were used in humans
in the mid-1980s [1]. In 1991, Medtronic® released the
first programmable pump for human use [2]. The majority
of the research and reports concern programmable
pumps, and the best and most current systematic review
of the literature only identified manuscripts on these
devices, and only considered chronic nonmalignant pain
(AKA chronic noncancer pain [CNCP]) [1]. Older reviews
are available [3–5]. No review, nor our literature search,
identified a randomized controlled trial (RCT) of implant-
able pumps using opioids in CNCP; yet despite such lack
of evidence, the devices are commonly used for patients
with CNCP. In contrast, there is a Food and Drug Admin-
istration drug registry of RCTs available for implantable
pumps using ziconotide in CNCP [6]; Intrathecal (IT)
baclofen has been assessed for spasticity (but no RCT;
see Taricco et al. [7]) and in the management of the dys-
tonia of complex regional pain syndrome [8]. There is a
good RCT of implantable pumps using opioids in cancer
pain showing modest efficacy, but substantial risk [9].
Case reports, open label series and anecdotes abound for
opioid pumps in CNCP, but no RCT. The most remarkable
feature of this embarrassing situation is that the function-
ality of the device and the physiological/pharmacological
interface actually inherently lend themselves to the RCT.
Randomization is straightforward. The device can easily be
programmed to deliver or not deliver drug, leading to an
excellent patient/subject blind. The side effects of delivery
could theoretically unblind the subject, but most of these
are subtle and cumulative (and that feature can and should
be definitively tested, for instance with active controls).
Additionally, all operators except the programmer can be
blinded, making a “one and a half blind” simple to imple-
ment. Why an RCT in a standard chronic pain model with
standardmethodology has not be performed after 25 years
of use is a (partial) mystery. The lack of funding pretext is not
rational, as the high profitmargin from these devices should
be persuasive to industry support for executing definitive
efficacy experiments. So what then, is the hold up?
A risk–benefit analysis is difficult to assess in the absence
of evidence of efficacy, but reviews of complications raise
concerns about the procedure. In the Turner et al. sys-
tematic review, the weighted mean suggests that 41%
had urinary retention, 37% of whom required catheteriza-
tion “for several days;” nausea/vomiting, 33%; pruritus,
26%; “catheter-related complications” (migration, occlu-
sion, or mechanical failure), 18%; pump “malposition,”
17%; wound infection, 12%; and meningitis 3%. The
Perez et al. review of baclofen IT pumps mentions post
lumbar puncture headache [8], but Turner concludes this
is “not . . . common . . .” [1]. Of the patients, 27%
required “equipment revisions” (Turner). Many other com-
plications are reported rarely (see Table 5 in Turner et al.)
[1]. Serious side effects are reported rarely. There have
been two overdose deaths reported due to operator error.
Other serious documented side effects include IT granu-
lomas with neurologic dysfunction, traumatic syrinx, trans-
verse myelitis, and withdrawal symptoms with pump
failure or removal [1]. The cost of IT pumps is very sub-
stantial. The original implantation can run $30,000–
40,000, with periodic refills (as often as monthly) running
$500/visit and up. Again, without clear efficacy data it is
difficult to assess the cost–benefit ratio.
The rationale for “resorting” to opioid pumps in chronic
pain often relies on the argument that pain is “intractable”
or “refractory;” however, the available literature indicates
that this usually means failure of a modest array of
sequential drug trials to provide adequate reported relief,
and not optimized efficacious interdisciplinary care [10].
In the spirit of “responsible use and development,” we
must conclude that there is a critical and immediate need
for good science in the use of IT pumps, specifically
concerning the common use of opioids in implantable
pumps for the management of refractory chronic pain
conditions. Until evidence is available, this technology
might even be considered experimental, and as such the
ethics of continuing to use (and bill for) this intervention
(after 25 years of empirical use) is questionable. The des-
peration of patients in chronic pain, and the desire for
simple, immediate gratification may justify early use of a
technology for compassionate reasons, but after a quarter
century simple empiricism is no longer tenable.
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